Anti-Helicobacter pylori Monoclonal Antibody Developed for IHC Staining

pylori antibody provides pathologists with excellent views of the bacterium, allowing for a more accurate patient diagnosis. The high contrast staining of the organisms allows pathologists to view more bacteria than can be detected with special stains. With the H. pylori antibody, a pathologist can clearly view the characteristic helical shape of the organism. Even when very few organisms are present, an infection can be detected and treated effectively.

The Ventana anti-Helicobacter pylori (SP48) rabbit monoclonal primary antibody is the first H. pylori antibody to receive 510(k) clearance from the US Food and Drug Administration (FDA; Silver Spring, MD, USA). The antibody was developed by Ventana Medical Systems, Inc. a member of the Roche Group (Basel, Switzerland).

The Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) estimates that approximately two-thirds of the world's population harbors the H. pylori bacterium, which damages the mucous coating that protects the stomach and duodenum. H. pylori causes peptic ulcers in nine out of 10 cases and studies have shown that those infected with H. pylori are nearly six times more likely to develop gastric cancer than those uninfected.

Related Links:
Ventana
Roche
Centers for Disease Control and Prevention